# US 10,766,951 B2 · Antibodies against infectious diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,951 B2
- Document ID: US10766951B2
- Status: Granted
- Kind: B2
- Application number: 15/563,614
- Filed: 2016-04-01
- Published: 2018-11-08
- Granted: 2020-09-08
- Earliest claimed: 2015-04-01
- Assignees: Taipei Medical University
- Applicants: Taipei Medical University
- Inventors: Sy-Jye Leu; Yi-Yuan Yang; Yu-Ching Lee; Ching-Hua Su; Ko-Jiunn Liu; Hsiu-Jung Lo; Yun-Liang Yang
- Web page: https://patentgrep.com/patent/US10766951B2

## CPC

- C07K 16/14: against material from fungi, algea or lichens
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/10: Antimycotics
- C07K 16/02: from eggs
- C07K 16/18: against material from animals or humans
- C07K 16/40: against enzymes
- C12N 9/60: from yeast
- C12N 9/88: Lyases (4.)
- C12Y 402/01011: Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
- G01N 33/56938: {Staphylococcus}
- G01N 33/56944: {Streptococcus}
- G01N 33/56961: {Plant cells or fungi}
- G01N 33/573: for enzymes or isoenzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/23: from birds
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/40: from Candida
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Anti-CaENO1 antibodies and humanized antibodies are provided as an effective diagnostic agent or a therapeutic treatment against infections caused by Candida spp., preferably Candida albicans, Candida tropicalis, fluconazole resistance Candida spp., Streptococcus, Staphylococcus.

## Claims

### Claim 1

An isolated anti-CaENO1 antibody or an antigen-binding portion thereof, comprising a light chain complementarity determining region 1 (L-CDR1) of SEQ ID NO:5; a light chain CDR2 (L-CDR2) of SEQ ID NO:6; and a light chain CDR3 (L-CDR3) of SEQ ID NO:7; and a heavy chain CDR1 (H-CDR1) of SEQ ID NO:8; a heavy chain CDR2 (H-CDR2) of SEQ ID NO:9; and a heavy chain CDR3 (H-CDR3) of SEQ ID NO:10; such that said isolated antibody or antigen-binding portion thereof binds to CaENO1.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the isolated anti-CaENO1 antibody is a monoclonal antibody, chimeric antibody or humanized antibody.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the light chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:13 and 14; or wherein the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 16.

### Claim 4 (depends on 1)

The antibody of claim 1, which is a humanized antibody comprising (i) a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs:13 and 14, and (ii) a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs:15 and 16.

### Claim 5 (depends on 4)

The humanized antibody of claim 4, which comprises:
(i) a light chain having an amino acid sequence of SEQ ID NO:13 and (ii) a heavy chain having an amino acid sequence of SEQ ID NO: 15 or
(iii) a light chain having an amino acid sequence of SEQ ID NO: 14 and (iv) a heavy chain having an amino acid sequence of SEQ ID NO: 16.